Samumed may be the most successful Turkish initiative ever made. If you ask me what is samumed? We can call it an attempt to solve many health problems like aging and Alzheimer’s. Three Turkish entrepreneurs living in America; Osman Kibar, Cevdet Samikoglu, Yuzuf Yazıcı have announced and announced a venture partnership that will change the fate of the world. This innovative work, after being disclosed, received $ 300 million in support from an investor who himself suffers from health problems.
Let’s go into the details of our news. As we mentioned above, three Turkish entrepreneurs living in America were high school friends at the same time. Over time, they decided to establish an initiative with the innovation of Osman Kibar’s revolution in biology. Osman Kibar succeeded in synthesizing a protein that allows control of the cell in our body. This protein synthesis has attracted great interest both in the Turkish press and in the world press. Three friends called the initiative “Samumed“. The Samumed team continued to work in the field of long-lasting biotechnology. The value of this young company was $ 300 million. However, they soon managed to achieve a huge success and raise the company value to 12 billion dollars. How did that happen? Osman Kibar, a partner of the company, succeeded in synthesizing a protein that could control the cells in our body after long and exhausting studies. When this news was heard, investors in the pharmaceutical sector, which is one of the largest sectors in the world, were attracted attention. After the news, a renowned investor invested heavily in the company to develop this project.
Biotechnology is an innovative discipline that combines human biology with technology to find solutions to health problems. When you think about health problems in the world, you can imagine how valuable it would be for the stock market to solve only one of them. Thanks to biotechnological developments, we can gain access to the age of transhumanism as in science fiction films. So we can solve our illnesses, weaknesses and problems through biotechnological developments. The best example of this is Alzheimer’s disease. This illness comes with old age. Stopping aging, repairing brain cells is a key task for resolving this disease. With the new protein that Samumed project created, it could be a fundamental solution to this disease. This initiative is supported and progressed. At the same time, protein synthesis, the most difficult part of the job, has already been achieved.
Samumed: It is a biotechnology enterprise founded by three high school friends. Samumed, you continue to work as Siego-based. The company aims to remove many diseases such as baldness, aging, wrinkles, cancer, Alzheimer’s, joint pain, etc. thanks to the developed protein that can be directed. The goal of this institution, which aims to stop aging, can be a bit exaggerated. However, the project was established seven years ago and is moving firmly towards this goal. The company, which reached $ 12 billion in a very short period of time, proves how successful it is and attracts the attention of visionary entrepreneurs. As an investment recommendation, we would like to state that the value of the company may increase much more in the future.
What is the WNT?
WNT: A stem cell protein that is one of the basic stones of the cells in our body. Over time, this protein controls the organization of the cell and decides which cell it will turn into. If this protein is reduced in your body, aging is increasing. This protein structure is one of the main causes of cancer at the same time. If the correct use of this protein is achieved, there is a rejuvenating effect that stops aging. At the same time the producer can be the definitive solution of diseases like cancer because it is a protein. The technology that activates the WNT protein with signal transduction between cells is available for the treatment of diseases such as colon cancer, degenerative disc disease, tendinopathy, and aesthetic problems related to aging such as wrinkles.
With the proven success of the developments, Samumed received an investment of $ 300 million last week and the value of the company continues to increase day by day. Osman Kibar, who succeeded in synthesizing this protein at the same time as the company’s founder, was on the cover of Forbes magazine last year. One of the company’s biggest investors told us about the value of the company: “Even if they can produce a millimeter of cartilage, they become a bigger company than Apple.”
You can share your comments about this great initiative created by the three Turkish entrepreneurs in our comments.